Phase 3 TETON-1 data show inhaled treprostinil reduced FVC decline by 130 mL and cut clinical worsening risk 33% in IPF patients over 52 weeks, according to Steven Nathan, MD.
Steven Nathan, MD.
Advertisement
Steven Nathan, MD, Schar Chair of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and chair of the TETON Steering Committee.
Articles by Steven Nathan, MD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD
2
Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial
3
Q&A: How Lifelong Burdens Are Shaped by Childhood Eczema, With Delphine Kerob, MD
4
FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation
5